2 Outperform Rated Small Caps with Recent Pull-backs

The article highlights two Zacks-rated 'Outperform' small-cap stocks, Elite Pharmaceuticals (ELTP) and TSS, Inc. (TSSI), which experienced recent pullbacks despite strong quarterly results. ELTP, a generic drug manufacturer, reported a 78.3% revenue increase to $31.9 million and a significant rise in operating income for Q4 FY25, driven by its ADHD market presence, with its stock decline attributed to a non-cash warrant charge and competition concerns. TSS, Inc., an AI infrastructure provider, posted a 262% sales surge to $44 million in Q2 and raised its 2025 adjusted EBITDA growth guidance to 75%, with its stock pullback linked to flat EPS due to new facility depreciation. Both companies' pullbacks are presented as potentially excessive, offering attractive entry points given their underlying growth drivers and strategic positioning in their respective markets.

Analysis

This analysis covers two small-cap stocks, Elite Pharmaceuticals (ELTP) and TSS, Inc. (TSSI), which have experienced share price pullbacks despite reporting fundamentally strong quarterly results. Elite Pharmaceuticals posted robust fourth-quarter fiscal 2025 figures, with revenue growing 78.3% year-over-year to $31.9 million and operating income increasing to $11.2 million from $3.7 million. This performance is driven by its significant foothold in the generic ADHD market, holding approximately 20% of the Adderall IR and 16% of the Adderall ER markets, and its recent successful entry into the generic Vyvanse market. The stock's decline is attributed to several factors: a non-cash $7.2 million warrant charge that negatively impacted EPS, investor concerns over increased competition and potential pricing erosion in the generic space, and strategic uncertainty regarding a potential sale of the business. Separately, TSS, Inc., an AI infrastructure provider, reported a 262% sales increase to $44 million in its recent Q2 and raised its 2025 adjusted EBITDA growth guidance to at least 75%. Despite this top-line acceleration, the stock pulled back nearly 30%, a move linked to flat year-over-year EPS of $0.06. This was primarily due to higher, and expected, depreciation expenses from a new 213,000-square-foot facility built to accommodate future growth, an investment management projects will be profitable within two years. While TSSI's growth is directly tied to the AI boom, its primary risk is its high customer concentration, with nearly all revenue dependent on a single client.

Key Decisions for Investors

• Investors should assess whether Elite Pharmaceuticals' impressive 78.3% revenue growth and strong ADHD market share justify its premium valuation, while considering the articulated risks of pricing pressure from competition and uncertainty related to a potential business sale.
• The nearly 30% pullback in TSS, Inc. may present an attractive entry point for exposure to AI infrastructure growth, but this opportunity must be carefully weighed against the significant concentration risk tied to its single largest customer.
• Consider that the market may have overreacted to non-operational factors for both companies, namely ELTP's non-cash warrant charge and TSSI's fully-expected depreciation expenses from strategic growth investments.
• Monitor ELTP's future gross margins for signs of sustained pricing power amidst competition, and track the capital expenditure forecasts of major IT companies as a key proxy for future demand for TSSI's integration services.